<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861728</url>
  </required_header>
  <id_info>
    <org_study_id>20170064</org_study_id>
    <nct_id>NCT03861728</nct_id>
  </id_info>
  <brief_title>Viral Conjunctivitis Treatment Study</brief_title>
  <official_title>Avenova for the Treatment of Viral Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novabay Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid)
      in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated
      with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral
      Conjunctivitis compared with artificial tears.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Avenova® is a proprietary pure hypochlorous acid under a family of skin cleansing products by
      NovaBay that has been cleared by the FDA as a 510(k) medical device. Many in vitro studies
      have evaluated the efficacy of hypochlorous acid against microbacterial and viral agents. In
      ophthalmology, it is commonly used as a lid cleanser in the treatment of blepharitis and
      meibomian gland dysfunction. It is applied directly to the lid margin and has an excellent
      skin and ocular safety profile, which includes a lack of ocular irritation on application.The
      investigators propose a study to evaluate the role of Avenova® (0.01% hypochlorous acid) in
      the treatment of common ocular viral infections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>A second investigator will randomize the patient to Treatment vs Placebo on initial visit. This &quot;second investigator&quot; will not be involved in screening or follow-up patient visits. At the end of the study the patient arms will be unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical resolution of viral conjunctivitis</measure>
    <time_frame>2 weeks</time_frame>
    <description>Clinical resolution of viral conjunctivitis as defined by clinical questionnaire and clinical examination. Each visit the patient will be asked a subjective questionnaire which includes symptoms of irritation, tearing, photophobia, discharge, and decreased vision on a none to always scale. Symptomatic resolution of viral conjunctivitis will be considered when the patient answers &quot;rarely&quot; to the list of symptoms. On clinical examination, the patient's visual acuity, intraocular pressure will be checked, and measures of inflammation including corneal surface disease, follicular response of the conjunctiva, scarring of the conjunctiva, and edema of the conjunctiva will be followed on a 0-3 scale. Resolution of viral conjunctivitis will be defined as a 0 or 1 on the follicular conjunctivitis scale with 0 or 1 on the conjunctival injection score. The time to resolution will then be compared.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Viral Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Viral Conjunctivitis Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with 0.01% Hypochlorous acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viral Conjunctivitis Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with Basic Sterile Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>0.01% Hypochlorous acid</intervention_name>
    <description>Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)</description>
    <arm_group_label>Viral Conjunctivitis Treatment</arm_group_label>
    <other_name>Avenova</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to be used four times a day to the affected eye for 2 weeks</description>
    <arm_group_label>Viral Conjunctivitis Placebo</arm_group_label>
    <other_name>Basic Sterile Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting to the Bascom Palmer Eye Institute

          -  Clinical diagnosis of viral conjunctivitis

          -  Symptoms less than 1 week duration

        Exclusion Criteria:

          -  history of allergic conjunctivitis

          -  history of herpetic eye disease

          -  concurrent diagnosis of bacterial conjunctivitis (based off microbiology plating)

          -  Immunocompromised / Immunosuppressed patients

          -  Patients with HIV

          -  pregnant women

          -  prisoners

          -  adults who are unable to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bascom Palmer Eye Institute, University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Rong, MD</last_name>
    <phone>3053266000</phone>
    <email>ajr211@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Lee, MD</last_name>
      <phone>305-326-6434</phone>
      <email>wlee@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Debabov D, Noorbakhsh C, Wang L, et al. Avenova™ with Neutrox™ (pure 0.01% HOCl) compared with OTC product (0.02% HOCl). NovaBay Pharmaceuticals, Inc., Emeryville, California, USA</citation>
  </reference>
  <results_reference>
    <citation>Kim HJ, Lee JG, Kang JW, Cho HJ, Kim HS, Byeon HK, Yoon JH. Effects of a low concentration hypochlorous Acid nasal irrigation solution on bacteria, fungi, and virus. Laryngoscope. 2008 Oct;118(10):1862-7. doi: 10.1097/MLG.0b013e31817f4d34.</citation>
    <PMID>18677274</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Wendy Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Viral</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

